Bevacizumab with immunotherapy for liver cancer

Patients with unresectable hepatocellular carcinoma (HCC)treated with the addition of durvalumab and bevacizumabto the standard of care with transarterial chemoembolization(TACE) showed significant improvement in progression-freesurvival (PFS) in comparison with those treated with TACEalone according to results of the phase 3 EMERALD-1 trial,which was presented at the 2024 ASCO GastrointestinalCancers Symposium.

Copyright © 2020 Terumo India Private limited

Important information regarding

By using this website, you consent to the use of cookies in accordance with our